TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
HK Stock MarketDetailed Quotes
01167 JACOBIO-B
- 1.290
- -0.030-2.27%
Market Closed Dec 20 16:08 CST
1.02BMarket Cap-2.56P/E (TTM)
1.320High1.270Low215.40KVolume1.300Open1.320Pre Close277.99KTurnover0.03%Turnover RatioLossP/E (Static)788.82MShares3.71052wk High1.02P/B1.02BFloat Cap1.25052wk Low--Dividend TTM788.82MShs Float25.350Historical High--Dividend LFY3.79%Amplitude1.250Historical Low1.290Avg Price300Lot Size--Div YieldTTM--Div Yield LFY
JACOBIO-B News
Express News | The USA Biological Security Act was not included in the CR bill.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
JAKAS (01167.HK) presented clinical data for a drug treating bone marrow fibrosis in the usa.
JAKS-B (01167.HK) announced that at the 66th American Society of Hematology (ASH) Annual Meeting held in San Diego, California in 2024, preliminary data from the Phase I clinical trial of the BET inhibitor "JAB-8263" for the treatment of myelofibrosis (MF) were presented. The data indicates that "JAB-8263" has good tolerability, with a recommended Phase II dose of 0.3 mg (administered daily). Preliminary efficacy data for the use of "JAB-8263" as a monotherapy for myelofibrosis is encouraging, with most patients experiencing splenic size reduction and a decrease in total symptom scores. JAKS-B revealed.
JACOS-B (01167.HK) presented initial clinical data on the BET inhibitor JAB-8263 for the treatment of myelofibrosis at the 66th annual conference of hematology in 2024 in the usa.
On December 9, Gelonghui reported that Jianghe Science-B (01167.HK) announced that it showcased preliminary data from a phase I clinical trial of the BET inhibitor JAB-8263 for treating myelofibrosis (MF) at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California, in 2024. The data showed that JAB-8263 has good tolerance, with a recommended dose of 0.3 mg (daily administration) for phase II. The initial efficacy data for JAB-8263 monotherapy for the indication of myelofibrosis is encouraging, with most patients experiencing spleen shrinkage.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.
Jacobio Pharmaceuticals Completes Dosing for Anti-Cancer Drug Clinical Trial in China
Many innovative drugs stocks in Hong Kong suddenly soared!
On the morning of November 25, the hang seng index fell slightly, while the Hong Kong stock market's biomedical sector performed well. Notably, several biomedical companies saw their stock prices rise significantly due to recent news of major collaboration advancements.
JACOS-B (01167.HK): Completed the first administration of the pan-KRAS inhibitor JAB-23E73 in a Phase I/IIa clinical trial in china.
Global November 25th丨Jax-B (01167.HK) announced that the company's self-developed pan-KRAS inhibitor JAB-23E73 has completed the first patient dosing in Phase I/IIa clinical trials in China. KRAS is widely present in mutations of various tumors, with about 23%-25% of cancer patients carrying KRAS mutations, and it is expected that approximately 2.7 million new tumor patients with KRAS-related mutations worldwide each year may benefit from pan-KRAS inhibitors. JAB-23E73 can simultaneously inhibit the active and inactive states of KRAS, as well as HRAS.
Jaccase (01167) initiated the first clinical study of pan-KRAS inhibitor.
Gilead initiates the first clinical study of pan-KRAS inhibitors.
October 25th buyback collection | HSBC Holdings, AIA and others have successively repurchased, with HSBC Holdings spending 65.7889 million Hong Kong dollars.
According to the disclosure documents released by hkex on October 28, hsbc holdings (00005.HK), aia (01299.HK), and others repurchased shares. ① hsbc holdings (00005.HK) repurchased 0.96 million ordinary shares on October 24, involving 65.7889 million Hong Kong dollars, with a repurchase price per share ranging from 68.75 Hong Kong dollars to 68.2 Hong Kong dollars. ② aia (01299.HK) repurchased 0.9856 million ordinary shares on October 25, involving 62.3662 million Hong Kong dollars, with a repurchase price per share ranging from 64.3
October 21st Buyback Compilation | hsbc holdings, aia and others have successively repurchased, with hsbc holdings spending 0.102 billion Hong Kong dollars.
According to the disclosure documents released by hkex on October 22, hsbc holdings (00005.HK) and aia (01299.HK) repurchased shares. ① Hsbc holdings (00005.HK) repurchased 1.484 million shares of common stock on October 18, involving 0.102 billion Hong Kong dollars, with the repurchase price per share ranging from 69.1 Hong Kong dollars to 68.4 Hong Kong dollars. ② Aia (01299.HK) repurchased 1.002 million shares of common stock on October 21, involving 62.3921 million Hong Kong dollars, with the repurchase price per share ranging from 62.9 Hong Kong dollars.
On October 21st, Gaxca-B (01167.HK) spent 0.123 million Hong Kong dollars to repurchase 0.0654 million shares.
Gelonghui October 21st | Jakes-B (01167.HK) announced, on October 21, 2024, the company spent 0.123 million Hong Kong dollars to repurchase 0.0654 million shares.
Jacobio Pharmaceuticals' Cancer Drug Gets Orphan Drug Designation From European Medicines Agency
October 18th buyback collection | HSBC Holdings, AIA and others have repurchased, with HSBC Holdings spending 0.101 billion Hong Kong dollars.
According to hkex disclosure on October 21, hsbc holdings (00005.HK), aia (01299.HK), and others repurchased shares. ① hsbc holdings (00005.HK) repurchased 1.4864 million shares of common stock on October 17, involving an amount of 0.101 billion Hong Kong dollars, with a repurchase price per share ranging from 68.55 Hong Kong dollars to 67.55 Hong Kong dollars. ② aia (01299.HK) repurchased 0.9878 million shares of common stock on October 18, involving an amount of 61.8387 million Hong Kong dollars, with a repurchase price per share ranging from 63.
Jaccard-B (01167.HK): Golirex approved for orphan drug therapy indication for pancreatic cancer in europe.
Gecoris-B (01167.HK) announced on October 21 that its main research and development KRAS G12C inhibitor Glecirasib was granted orphan drug therapy designation for pancreatic cancer by the European Medicines Agency. Pancreatic cancer is a highly malignant tumor, with patients currently lacking effective standard treatment options. The overall five-year survival rate for advanced pancreatic cancer is only 3.1%. Previously, the indication for Glecirasib in pancreatic cancer received orphan drug therapy designation in the USA by the US Food and Drug Administration and breakthrough therapy designation by the National Medical Products Administration's Drug Evaluation Center in China.
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
October 9th buyback assembly | Tencent Holdings, HSBC Holdings and others have successively repurchased, with Tencent Holdings spending 0.703 billion Hong Kong dollars.
According to the documents disclosed by hkex on October 10th, tencent ($00700.HK$), hsbc holdings ($00005.HK$), and others repurchased shares. ① Tencent ($00700.HK$) repurchased 1.6 million ordinary shares on October 9, involving an amount of 0.703 billion Hong Kong dollars, with the repurchase price ranging from 450.4 Hong Kong dollars to 424 Hong Kong dollars per share. Since the repurchase authorization resolution, the total number of repurchased securities is 0.178 billion shares, accounting for 1.887% of the number of issued shares when the ordinary resolution was passed. ② HSBC Holdings ($00005.HK$) on October
October 8th buyback rally | Tencent Holdings, HSBC Holdings and others have successively repurchased, with Tencent Holdings spending 0.703 billion Hong Kong dollars.
According to hkex's disclosure on October 9th, tencent holdings (00700.HK) and hsbc holdings (00005.HK) repurchased shares. ① Tencent Holdings (00700.HK) repurchased 1.56 million ordinary shares on October 8, involving 0.703 billion Hong Kong dollars, with a repurchase price per share ranging from 474.8 Hong Kong dollars to 438.6 Hong Kong dollars. Since the repurchase authorization resolution, the cumulative number of repurchased securities is 0.176 billion shares, accounting for 1.87% of the number of shares issued at the time of the ordinary resolution. ② HSBC Holdings (00005.HK) on October
Trending HK Stocks
HK Tech and Internet Stocks HK Tech and Internet Stocks
Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data. Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data.
